Clinical and detailed angiographic findings in patients with ambulatory electrocardiographic ischemia without critical coronary narrowing: results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) Study

BACKGROUND

Patients with ambulatory electrocardiographic (AECG) ST-segment depression and critical coronary narrowing are known to be at increased risk for adverse outcome, but little is known about patients with AECG ST-segment depression without critical coronary narrowing.

HYPOTHESIS

The objectives of this study were to characterize the coronary angiographic pathology in patients with AECG ST-segment depression but without critical (< 50% diameter stenosis) coronary narrowing and to compare demographic and clinical findings in these patients with those enrolled in the Asymptomatic Cardiac Ischemia Pilot Study with AECG ST-segment depression and critical (> or = 50% diameter stenosis) coronary narrowing.

METHODS

Coronary angiograms from patients with AECG ST-segment depression were reviewed in a central laboratory and quantitative measurement of percent stenosis was performed. Clinical and angiographic comparisons were made between patients with and without critical coronary narrowing.

RESULTS

Patients without critical coronary narrowing (n = 64) were younger (p = 0.02), less likely to be male (p < 0.001) or to have risk factors for coronary atherosclerosis or a history of myocardial infarction (p < 0.001), and had fewer ischemic episodes per 24 h on the screening AECG (p = 0.02) than patients with critical coronary narrowing (n = 441). Of patients without critical narrowing, one half had angiographic evidence for coronary artery disease (> or = 20% stenosis) and 60% had an ejection fraction > 70%.

CONCLUSIONS

Patients with AECG ST-segment depression without critical coronary narrowing are heterogeneous, with half having measurable coronary artery disease. Demographically and clinically, they appear to be different than patients with AECG ST-segment depression with critical coronary narrowing.

Continuing medical education and industry support

1. Industry and faculty of continuing medical education programs must agree that any supported program is for scientific and educational purposes only and not to promote a company's products directly or indirectly. 2. The control of content and selection of presenters and moderators must be independent of the company and determined by the program director. 3. Faculty of continuing medical education programs must disclose any financial relationship they have with the sponsoring company. 4. Program content cannot be scripted or influenced in any way by industry. 5. Objectivity and balance must be perceived by the audience. This includes the presentation of favorable and unfavorable information and alternative treatments. 6. Incomplete data must be identified by the faculty. Oftentimes, much of what is presented at continuing medical education programs has not yet been published in peer-reviewed journals. This must be so indicated by the presenter, and it should be specified whether incomplete data is on-going research, analysis, preliminary data, or unsupported opinion. 7. Support from industry must be in the form of an educational grant with no strings attached.

Intracardiac masses detected by echocardiography: case presentations and review of the literature

Intracardiac masses are often diagnosed by transthoracic echocardiography (TTE). Transesophageal echocardiography (TEE) improves overall visualization of masses, especially those located in the posterior cardiac structures. Masses in the heart are most commonly due to thrombi or valvular vegetations; however, a variety of tumors may also present as cardiac masses on echocardiography. Tumors of the heart most commonly occur in the setting of metastatic disease, usually from malignancies of the breast, lung, or from malignant melanoma. Primary cardiac tumors occur much less frequently and are usually benign. Atrial myxomas constitute nearly one-half of reported primary cardiac tumors. The following discussion details the findings of five cases that illustrate the spectrum of intracardiac tumors detected by echocardiography and reviews the relevant literature.

Low molecular weight heparin for acute ischemic heart disease

LMWH seems to me to be an attractive antithrombotic therapy that can be used in combination with antiplatelet treatment in patients with acute coronary syndromes. One of the advantages of LMWH is that home treatment becomes a possibility since the agent can be administered as subcutaneous injection without monitoring coagulation times. Therefore, in some patients, once they are stabilized and past the acute event, outpatient subcutaneous treatment with LMWH could be an attractive alternative to impatient treatment with intravenous heparin.